In a 54‑year‑old man with chronic kidney disease on maintenance hemodialysis who has bilateral lymphocyte‑predominant exudative pleural effusions (right larger) and normal pleural fluid adenosine‑deaminase, what is the most likely diagnosis and appropriate management?

Bilateral Lymphocytic Pleural Effusion in CKD on Hemodialysis

Most Likely Diagnosis

In a 54-year-old man with CKD on maintenance hemodialysis presenting with bilateral lymphocyte-predominant exudative pleural effusions (right larger than left) and normal pleural fluid ADA, the most likely diagnosis is fluid overload, followed by uremic pleuritis if aggressive dialysis fails to resolve the effusions. 1

Diagnostic Reasoning

Fluid Overload Remains the Leading Cause

• Fluid overload accounts for 61.5% of pleural effusions in hemodialysis patients, even when the effusion is exudative. 1, 2
• While fluid overload classically produces transudative effusions, repeated thoracentesis and chronic inflammation can convert transudates to exudates in dialysis patients. 3, 2
• The bilateral nature (right > left) strongly supports fluid overload, as 68.8% of effusions from hypervolemia are bilateral in hemodialysis patients. 2

Uremic Pleuritis as Secondary Consideration

• Uremic pleuritis is the most common cause of exudative pleural effusion in CKD patients (40% of exudative cases), typically presenting with lymphocytic predominance and often hemorrhagic fluid. 1, 4, 2
• This diagnosis should be considered if the effusion persists despite intensive dialysis. 1, 5

Tuberculosis is Effectively Excluded

• Normal pleural fluid ADA (<40 U/L) has high negative predictive value for excluding tuberculosis, with only 1.71% of non-tuberculous lymphocytic exudates reaching ADA ≥40 U/L. 6, 4
• The sensitivity of ADA for tuberculous pleurisy in CKD patients is only 66.7%, but its specificity is 90%, making a normal value reassuring. 4
• Even in high TB prevalence countries, uraemia remains the most common cause of pleural effusion in CKD. 4

Malignancy Requires Consideration

• Lymphoma accounts for 10-22% of malignant pleural effusions and characteristically presents with lymphocyte-predominant exudates. 7
• However, the bilateral presentation and dialysis context make fluid overload more likely. 1, 2

Diagnostic Approach

Initial Management Steps

1. Perform thoracic ultrasound to assess for pleural nodularity suggesting malignancy and to guide safe thoracentesis. 8
2. If not already done, send pleural fluid for complete analysis including protein, LDH, pH, glucose, cell count with differential, Gram stain, culture, and cytology. 8
3. Calculate Light's criteria and serum-to-pleural fluid albumin gradient to confirm exudative nature. 7

Therapeutic Trial

• Initiate aggressive fluid removal during dialysis sessions and strict salt/fluid restriction as first-line management. 1
• The 2024 European Respiratory Society guidelines emphasize that if the etiology is fluid overload, aggressive medical management or intensified renal replacement therapy adequately treats pleural effusions. 1
• Monitor response over 1-2 weeks with clinical assessment and repeat chest imaging. 1

If Effusion Persists Despite Aggressive Dialysis

Consider uremic pleuritis and proceed with:

• Increase intensity of dialysis (frequency and duration of sessions). 1
• Consider systemic corticosteroids (prednisone 1-2 mg/kg/day for 5-7 days, then taper over 6-8 weeks) for refractory uremic pleuropericarditis. 1, 5
• One case series demonstrated marked improvement in refractory uremic pleuropericarditis with corticosteroid therapy after conventional treatments failed. 5

Further Investigation if Non-Responsive

If effusions remain unexplained after 2-4 weeks of aggressive dialysis:

• Obtain contrast-enhanced CT chest (including abdomen/pelvis) to evaluate for occult malignancy, particularly lymphoma. 7, 8
• Consider medical thoracoscopy for direct visualization, targeted biopsy, and potential therapeutic pleurodesis. 8, 4
• Thoracoscopy has 100% sensitivity for tuberculosis when combined with multiplex PCR in CKD patients, though it carries complication risks. 4

Symptomatic Management

For Dyspnea Relief

• Offer serial therapeutic thoracentesis as first-line treatment for symptomatic relief, rather than indwelling pleural catheters. 1
• The 2024 ERS guidelines recommend serial thoracentesis over IPCs in dialysis patients due to high adverse event rates and increased drainage volumes with IPCs. 1
• Reserve indwelling pleural catheters or talc pleurodesis for refractory cases only. 1

Critical Pitfalls to Avoid

Do Not Empirically Treat for Tuberculosis

• With normal ADA and lymphocytic effusion, empirical anti-tubercular therapy is not indicated and was shown to be unsuccessful in preventing constriction in chronic effusions of undetermined etiology. 1, 4
• In developing countries, many effusions are empirically treated with anti-tubercular therapy without proper diagnosis, which should be avoided. 4

Recognize Poor Prognosis Markers

• Patients with ESRF who develop pleural effusions have 6-month and 1-year mortality rates of 31% and 46%, respectively—three times higher than the general ESRF population. 1
• This underscores the importance of aggressive investigation for treatable causes and optimization of dialysis adequacy. 1

Avoid Repeated Thoracentesis Without Clear Indication

• Frequent thoracentesis enhances pleural inflammation and can convert transudates to exudates, complicating the clinical picture. 3
• Limit diagnostic thoracentesis to initial evaluation and therapeutic thoracentesis to symptomatic relief only. 1, 3